摘要
目的:系统评价艾地苯醌治疗血管性痴呆的疗效。方法:计算机检索SCI、Pub Med、EMBASE、Cochrane Library、中国生物医学文献数据库、中国知网数据库、万方数据库和维普数据库,收集所有艾地苯醌治疗血管性痴呆的随机对照试验,检索时限均从建库到2018年04月01日。2位研究者独立筛选文献、提取数据、评价文献质量后,采用STATA 15.0软件进行Meta分析。结果:共纳入11个研究745例患者,Meta分析结果显示,艾地苯醌组的MMSE评分(WMD=2.28,95%CI 1.82~2.75,P=0.000)、ADL评分(Barthel指数评分)(WMD=2.04,95%CI 1.14~2.94,P=0.000)和总有效率(RR=1.15,95%CI 1.07~1.24,P=0.000)高于对照组,差异有统计学意义。结论:艾地苯醌能促进血管性痴呆患者的神经功能恢复,可用于血管性痴呆的治疗。
Objective： To systematically evaluate the effectiveness of idebenone versus conventional treatment for vascular dementia（VD）. Methods： Systematic searches were conducted in SCI,Pub Med,EMBASE,Cochrane Library,CBM,CNKI,Wan Fang,and VIP databases,to collect all relative randomized controlled trials（RCTs） on idebenone treating VD from inception to April 2018. Two reviewers independently screened articles according to the inclusion and exclusion criteria,extracted data and evaluated the quality of the included studies. Then statistical analysis was performed using STATA 15. 0. Results： A total of 11 RCTs involving 745 patients were included.The results of meta-analysis demonstrated that compared with the control group,the idebenone group was statistical significant higher in the MMSE score,Barthel index score,total effective rate,significant efficency. Conclusion： Current evidence showed idebenone promote recovery of neurological function in VD patients and can be used for VD treatment.
作者
赵俊杰
杨春华
ZHAO Jun-jie;YANG Chun-hua(Department of Neurology,Zhoukou Central Hospital,Henan Zhoukou 466000,China)
出处
《中国药物评价》
2018年第4期305-309,共5页
Chinese Journal of Drug Evaluation
